Arthur Tzianabos

Dr. Arthur Tzianabos joined 5AM in 2022 as a Venture Partner, bringing preeminent scientific and operational experience. Most recently, Dr. Tzianabos served as President and CEO of 5AM portfolio company, Homology Medicines, Inc. (Nasdaq: FIXX) where he led the company from inception through a successful public offering, taking developmental candidates into both gene editing and gene therapy clinical trials, and striking multiple validating business development deals including establishing a new company based on Homology’s innovative AAV process development and manufacturing platform. Previously, Dr. Tzianabos was SVP of Research and Early Development at Shire PLC (acquired by Takeda (NYSE: TAK), for $62B), and during his tenure he was responsible for building the company’s therapeutic pipeline and worked closely with the Venture group to make investments in genetic medicines companies. Earlier in his career, Dr. Tzianabos was a principal investigator and faculty member at Harvard Medical School for 13 years. He is a member of the board of directors for several companies, including Chair of 5AM portfolio companies Homology Medicines (Nasdaq: FIXX) and Akouos, Inc. (Nasdaq: AKUS), and serves on the Executive Committee of the Board of Directors for the Alliance for Regenerative Medicine and the Development Board for the University of New Hampshire’s College of Life Sciences and Agriculture. Dr. Tzianabos received his B.S. in biology from Boston College and his Ph.D. in microbiology from the University of New Hampshire.